Table 2.

SBRT for recurrence.

Study	N of patients	Primary disease	SBRT dose (Gy/number of fractions)	Local control	Overall survival	Local toxicity (N of patients/Grade)
Park et al. (2015)35	68	Cervix	39/3	79% at 5 years	58% at 2 years	5/GIII
Deodato et al. (2009)36	6	All Gyn	20–30/4–6	92% at 1 year	NR (PFS 2 year:81, 8%)	0/>GII
Yazici et al. (2013)37	16	Cervix	15–40/3–5	94% at 1 year	60% at 1 year	6/>GIII
Dewas et al (2011)38	16	Gyn + Gi + bladder	36/6	51% at 1 year	median OS 11 months	0/>GIII
Abusaris et al (2012)39	27	Cervix + other	16–45/2–6	53% at 2 years	NR	0/>GIII
Kunos et al (2012)40	16	All Gyn	24/3 fx	100% at 6 months	median OS 20 months	0/>GIII
Choi et al. (2009)30	30	Uterus + cervix		67% at 4 years	50% at 4 years	1/GIII
Seo et al. (2016)41	23	Uterus + cervix	27–45/3	65% at 2 years	43% at 2 years	3 recto vaginal fistulae